Pegcetacoplan is a complement C3 inhibitor (PEG peptide). It is filed in this library under heart & blood, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.
Regulatory status
Pegcetacoplan has an FDA-approved product on the U.S. market, marketed as Syfovre under application NDA217171.
The current label is held by Apellis Pharmaceuticals, Inc.
From the FDA label
is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).Quoted from the FDA-approved prescribing information
The evidence
One source on Pegcetacoplan, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.
Nearby
A 60-second questionnaire, reviewed by a U.S.-licensed physician.
Find my protocolEducational reference only. This page explains what has been published about Pegcetacoplan. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.
All 150 peptides